Compare Revvity Inc (RVTY) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Synopsys, Inc. — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Synopsys, Inc. trades at $509.81 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 5.6× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Synopsys, Inc. for 71 Days on average.
| RVTY | SNPS | |
|---|---|---|
Market Cap | $16.98B | $95.39B |
Volume | 1,456,900 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $157.36 | $534.56 |
52-Week Low | $82.26 | $367.70 |
Typical Hold Time | 12 Days | 71 Days |
Enterprise Value | $19.30B | $102.62B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Synopsys (SNPS) trades at $509.99, up 1.46% today, and is near its 52-week high. The stock exhibits a bullish technical trend with strong moving average support. Recent quarterly earnings have consistently beaten estimates, and the company's Investor Day in October 2026 highlighted transformative AI partnerships with OpenAI and Amazon, driving a 13% stock surge and upward revisions to long-term revenue guidance.
The outlook is positive, supported by robust analyst sentiment (93% buy ratings) and a consensus price target of $572.54. Key opportunities include AI-driven growth in chip design software and margin expansion from the Ansys acquisition. Risks involve high valuation multiples and integration execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
